XNASNERV
Market cap15mUSD
Dec 31, Last price
2.22USD
1D
-2.99%
1Q
-17.72%
Jan 2017
-97.64%
IPO
-95.41%
Name
Minerva Neurosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.06%
Rev. gr., 5y
%
Revenues
0k
Net income
-30m
L-23.04%
CFO
-15m
L-40.01%
Earnings
Feb 20, 2025
Profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
IPO date
Jun 25, 2014
Employees
9
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 23,120 | 25,240 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (23,120) | (25,240) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (2) | 6,877 | |||||||
Tax Rate | |||||||||
NOPAT | (23,120) | (32,117) | |||||||
Net income | (30,005) -23.04% | (38,986) -21.88% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 20,000 | ||||||||
BB yield | -49.98% | ||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | 82,017 | 73,734 | |||||||
Deferred revenue | (73,735) | ||||||||
Other long-term liabilities | 862 | 73,734 | |||||||
Net debt | 69,015 | 37,640 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (14,785) | (24,645) | |||||||
CAPEX | 2 | (16) | |||||||
Cash from investing activities | (16) | ||||||||
Cash from financing activities | 19,604 | (5) | |||||||
FCF | (20,426) | 1,408,770 | |||||||
| Balance | |||||||||
Cash | 41,013 | 36,094 | |||||||
Long term investments | (28,011) | ||||||||
Excess cash | 13,002 | 36,094 | |||||||
Stockholders' equity | (396,815) | (366,810) | |||||||
Invested Capital | 450,375 | 420,518 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 6,506 | 5,340 | |||||||
Price | 6.15 286.79% | 1.59 -75.19% | |||||||
Market cap | 40,014 371.26% | 8,491 -75.19% | |||||||
EV | 109,029 | 46,131 | |||||||
EBITDA | (23,089) | (25,231) | |||||||
EV/EBITDA | |||||||||
Interest | 8,283 | 7,407 | |||||||
Interest/NOPBT | |||||||||